HOWL
Werewolf Therapeutics Inc (HOWL)
Healthcare • NASDAQ • $0.68+9.68%
- Symbol
- HOWL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.68
- Daily Change
- +9.68%
- Market Cap
- $33.05M
- Trailing P/E
- N/A
- Forward P/E
- -0.69
- 52W High
- $2.38
- 52W Low
- $0.53
- Analyst Target
- $7.00
- Dividend Yield
- N/A
- Beta
- N/A
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activate…
Company websiteResearch HOWL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.